Novo Nordisk Seeks To Halt Sanofi Insulin Pen

Law360, New York (September 12, 2007, 12:00 AM EDT) -- Novo Nordisk A/S is asking a New Jersey federal court to stop Sanofi-Aventis sales of recently launched insulin pen SoloStar.

Novo Nordisk filed a motion for a preliminary injunction on Monday that would prevent Sanofi-Aventis and its U.S. affiliate from making and selling SoloStar in the U.S. until the conclusion of its patent infringement case.

Denmark-based drug-maker Novo says SoloStar is threatening its market share for pens and long-lasting insulin.

“Prompt resolution of Novo’s motion for preliminary injunction is essential here because the importation, sale, and...
To view the full article, register now.